[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebral-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebral-hemorrhage":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,42,100,133,163,188,231,262,283,322],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100576111","descriptive-study-on-mri-contrast-of-acute-cerebral-hemorrhage-in-different-microangiopathies-100576111",false,"NCT06781034","Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies","GADO-ICH","Inclusion Criteria:\n\n* Patients with acute cerebral hematomas from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy managed at Nîmes University Hospital;\n* Patients who have undergone a follow-up cerebral CT scan in the event of worsening or for follow-up.\n\nExclusion Criteria:\n\n* Patient refusing to participate","ALL","18 Years",{"count":19,"type":20},128,"ESTIMATED","OBSERVATIONAL","Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment.\n\nArterial contrast (\"spot sign\") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis.\n\nAn equivalent marker has also been described in gadolinium-enhanced MRI.\n\nBy studying the radiological appearance of gadolinium \"spot signs\" on MRI, which has better parenchymal resolution, the researchers propose to retrace the phenomenology of the acute phase of cerebral hemorrhage in order to better estimate the risk of radiological aggravation by subgroup, which could serve as a target population for future therapeutic trials.",[24,25],"Cerebral Hemorrhage","Acute Lobar Haematoma",[27,28],"Cerebral haemorrhage","MRI","RECRUITING","2026-06-29",{"date":32,"type":33},"2026-07-01","ACTUAL",{"date":35,"type":33},"2025-02-03",{"date":37,"type":20},"2026-12",{"name":39,"class":40},"Centre Hospitalier Universitaire de Nīmes","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":82,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100270060","neurologic-stem-cell-treatment-study-100270060","NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.",{"count":51,"type":20},500,"INTERVENTIONAL",[54],"NA","This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[57,58,59,60,61,62,63,64,65,66,67,24,68,69,70,71,72,73,74,75,76,77,78,79,80,81],"Neurologic Disorders","Nervous System Diseases","Neurodegenerative Diseases","Neurological Disorders","Stroke","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Infarction","Cerebral Ischemia","Cerebral Stroke","Parkinson","Multi-System Degeneration","MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","ALS","Amyotrophic Lateral Sclerosis","Neuropathy","Diabetic Neuropathies","Alzheimer Disease","Dementia","Frontotemporal Dementia","Lewy Body Disease","Cognitive Impairment","Lewy Body Variant of Alzheimer Disease",[83,84,61,62,85,86,74,87,66,80,77,88],"Neurologic Disease","Cerebral Vascular Accident","Multiple Sclerosis","Parkinsons Disease","Diabetic Neuropathy","Neurodegeneration","2026-06-24",{"date":91,"type":33},"2026-06-26",{"date":93,"type":33},"2016-06",{"date":95,"type":20},"2028-07-31",{"name":97,"class":98},"MD Stem Cells","INDUSTRY",3,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":52,"phases":110,"briefSummary":111,"conditions":112,"keywords":120,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":41},"100644087","efficacy-and-safety-of-antihypertensive-treatment-with-mobile-stroke-units-in-ultra-early-intracerebral-hemorrhage-100644087","NCT07665827","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage: A Multicenter, Prospective, Cluster-Randomized, Open-Label, Blinded-Endpoint Clinical Trial","MSU-ICH","Inclusion Criteria:\n\n1. History and physical\u002Fneurological examination consistent with acute stroke.\n2. Age ≥18 years;\n3. Time from symptom onset to enrollment \\\u003C3 hours (onset defined as last known normal).\n4. Systolic blood pressure ≥150 mmHg and ≤220 mmHg;\n5. Pre-stroke modified Rankin Scale (mRS) score ≤2;\n6. Informed consent obtained from the subject or a legally authorized representative.\n\nExclusion Criteria:\n\n1. Glasgow Coma Scale (GCS) score ≤5.\n2. Contraindications to intensive blood pressure lowering, including severe arterial stenosis or high-grade stenotic valvular heart disease.\n3. Malignant disease or other serious primary illness with a life expectancy of \\\u003C3 months.\n4. Current participation in another interventional randomized clinical trial.",{"count":109,"type":20},706,[54],"MSU-ICH is a prospective, multicenter, Week-wise-randomized, open-label, blinded-endpoint (PROBE) clinical trial comparing ultra-early prehospital blood pressure lowering delivered by a Mobile Stroke Unit (MSU) with standard Emergency Medical Services (EMS) in patients with spontaneous intracerebral hemorrhage.",[58,113,114,115,116,117,24,118,61,119],"Cerebrovascular Disorders","Cardiovascular Diseases","Vascular Diseases","Hemorrhage","Intracranial Hemorrhages","Cerebral Hemorrhage, Hypertensive","Hemorrhagic Stroke, Intracerebral",[121,122,123],"intracerebral hemorrhage","mobile stroke units","Intensive blood pressure lowering","NOT_YET_RECRUITING","2026-06-18",{"date":89,"type":33},{"date":128,"type":20},"2026-06",{"date":130,"type":20},"2028-07",{"name":132,"class":40},"Xuanwu Hospital, Beijing",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":52,"phases":144,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":158,"leadSponsor":160,"locationsCount":162},"100639019","early-lumbar-drainage-for-intraventricular-hemorrhage-100639019","NCT07625449","Early Lumbar Drainage for Intraventricular Hemorrhage","Effectiveness and Safety of Early Lumbar Drainage in the Treatment of Ventricular Hemorrhage: the LD-IVH Randomized Controlled Trial","LD-IVH","Inclusion Criteria:\n\n* Aged 18 to 85 years old, no limitation on gender.\n* First-ever intracerebral hemorrhage confirmed by CT\u002FMRI, accompanied by third and\u002For fourth intraventricular hemorrhage, requiring external ventricular drainage.\n* Baseline hemorrhage volume less than 30 mL, with stable clinical condition before randomization.\n* External ventricular drainage performed within 48 hours of symptom onset.\n* Randomization completed within 24 hours after EVD placement.\n* Pre-morbid modified Rankin Scale (mRS) score of 0 or 1.\n* Written informed consent obtained from the participant or their legally authorized representative.\n\nExclusion Criteria:\n\n* Suspected or untreated ruptured intracranial aneurysm, arteriovenous malformation (AVM), or intracranial tumor, unless excluded by vascular imaging. Previously treated aneurysm or AVM must have been completed at least 3 months prior to enrollment.\n* Choroidal vascular malformation or moyamoya disease.\n\n  • Long-term oral anticoagulant use, persistent coagulation dysfunction, or known allergy to urokinase.\n* Platelet count \\\u003C 100×10⁹\u002FL or INR \\> 1.4.\n* Absolute contraindications to lumbar cistern drainage or external ventricular drainage, such as cerebral hernia or infection at the puncture site.\n* Infratentorial hemorrhage volume ≥ 10 mL.\n* Thalamic hemorrhage ≥ 10 mL, or accompanied by midbrain extension, oculomotor nerve palsy, or fixed dilated pupil.\n* Hemiplegia with muscle strength grade 0 or 1.\n* Active bleeding in the gastrointestinal, genitourinary, or respiratory system.\n* Multiple ecchymoses or petechiae suggesting a bleeding tendency.\n* Expected survival time less than 6 months.\n* Severe, untreatable concomitant systemic diseases.\n* Pregnancy.\n* Participation in other interventional clinical trials within 30 days prior to randomization.\n* Any other condition deemed inappropriate for enrollment by the investigator(s).","85 Years",{"count":143,"type":20},392,[54],"This is a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) trial comparing the addition of early lumbar drainage to standard care in patients with intraventricular hemorrhage (IVH) in China. The primary objective is to evaluate whether early lumbar drainage improves long-term functional outcomes at 180 days, as measured by the modified Rankin Scale (mRS), and reduces complications in patients treated with external ventricular drainage (EVD) and intrathecal urokinase.",[147,24],"Intraventricular Hemorrhage",[147,149,150,151,152,153],"Lumbar Drainage","External Ventricular Drainage","Urokinase","PROBE design","Randomized Controlled Trial","2026-06-03",{"date":156,"type":33},"2026-06-04",{"date":128,"type":20},{"date":159,"type":20},"2029-10",{"name":161,"class":40},"Second Affiliated Hospital of Nanchang University",29,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":170,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":52,"phases":173,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":41},"100640279","a-cluster-randomized-trial-of-a-telemedicine-enabled-integrated-care-model-for-stroke-prevention-and-management-in-rural-elderly-adults-in-china-100640279","NCT07628283","A Cluster Randomized Trial of a Telemedicine-Enabled Integrated Care Model for Stroke Prevention and Management in Rural Elderly Adults in China","A Prospective, Open-Label, Cluster Randomized Controlled Trial to Evaluate the Efficacy of a Rural Doctor-Led, Telemedicine-Supported Integrated Care Model for Reducing Cardiovascular and Cerebrovascular Events in Elderly Adults at High Risk of Stroke in China","Inclusion Criteria:\n\n1. Aged 65 years or older\n2. Rural residents with household registration or long-term residence (≥6 months\u002Fyear) in the study area\n3. High risk of stroke as defined by the National Health Commission's \"8+2\" stroke risk screening tool: ≥3 risk factors OR history of stroke\u002FTIA\n4. Willing to receive long-term health management from the assigned village clinic\n5. Written informed consent provided by the participant or their legal representative\n\nExclusion Criteria:\n\n1. Severe dementia or psychiatric disorder that prevents completion of study follow-up and assessments\n2. Life expectancy less than 1 year (e.g., advanced malignancy, end-stage renal disease)\n3. Currently participating in another interventional clinical trial","65 Years",{"count":172,"type":20},2510,[54],"This cluster randomized controlled trial aims to evaluate the effectiveness of a novel telemedicine-enabled integrated care model led by rural doctors in reducing cardiovascular and cerebrovascular events among elderly adults (≥65 years) at high risk of stroke in rural China. A total of 39 village clinics will be randomized to either the intervention group (digital health platform-supported integrated care) or the control group (enhanced usual care). The primary outcome is a composite of cardiovascular death, stroke, and hospitalization for heart failure or acute coronary syndrome at 36 months.",[61,176,24,177,114,178],"Brain Ischemia","Transient Ischemic Attack","Hypertension","2026-05-28",{"date":181,"type":33},"2026-06-05",{"date":183,"type":20},"2026-06-01",{"date":185,"type":20},"2030-06-30",{"name":187,"class":40},"Jiangsu Province (Suqian) Hospital",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":197,"conditions":198,"keywords":204,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":41},"100637552","prospective-observational-multimodal-neuromonitoring-in-adult-nsicu-patients-100637552","NCT07577713","Prospective Observational Multimodal Neuromonitoring in Adult NSICU Patients","Prospective Observational Multimodal Neuromonitoring in Adult Neurosciences Intensive Care Unit Patients: Characterization of Noninvasive Cerebral Autoregulation Indices, Quantitative EEG, and Physiologic Correlates Across NSICU Diagnoses","Inclusion Criteria:\n\n* Age 18 years or older\n* Admitted to the NSICU at UT Southwestern Medical Center\n* Informed consent obtained from subject or legally authorized representative (as defined under Texas Health and Safety Code Section 166.039), or consent process underway per institutional policy\n* At least one study monitoring modality feasible (SedLine qEEG and\u002For Brain4Care extensometry); NIRS data collected where already in standard clinical use\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Prisoner status\n* Active declination of participation by subject or legally authorized representative\n* Absence of both subject and legally authorized representative consent when required\n* Clinical condition preventing safe placement of any study monitor (e.g., extensive facial or scalp injury, surgical dressings or hardware at all possible sensor sites, open wounds at sensor locations, severe uncontrolled agitation)\n* Anticipated clinical data capture insufficient for meaningful analysis\n* Urgent clinical priorities making research monitor placement inappropriate at time of approach\n* Inability to provide informed consent in English; study consent materials are available in English only",{"count":196,"type":20},300,"This is a prospective observational cohort study of adult patients admitted to the Neurosciences Intensive Care Unit (NSICU) at UT Southwestern Medical Center. The study acquires multimodal neuromonitoring data - including SedLine quantitative EEG (qEEG) from standard-of-care monitoring, Brain4Care (B4C) noninvasive intracranial dynamics monitoring, and near-infrared spectroscopy (NIRS)-derived cerebral autoregulation (CA) indices where NIRS is already in clinical use - and links these data to bedside physiologic, medication, diagnostic, and clinical outcome variables during standard care. No alteration of clinical management occurs. The study prioritizes aneurysmal subarachnoid hemorrhage (aSAH) patients to characterize the natural history of noninvasive CA parameter evolution through the delayed cerebral ischemia (DCI) window (admission through Day 14) and provides preliminary data for subsequent interventional study design.",[199,200,24,201,202,203],"Subarachnoid Hemorrhage, Aneurysmal","Brain Injuries, Traumatic","Ischemic Stroke","Delayed Emergence From Anesthesia","Encephalopathy",[205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221],"aneurysmal subarachnoid hemorrhage","delayed cerebral ischemia","cerebral autoregulation","CPPopt","MAPopt","Brain4Care","SedLine","quantitative EEG","near-infrared spectroscopy","COx","TOxA","transcranial Doppler","neurocritical care","NSICU","noninvasive intracranial monitoring","Moberg Clinical Platform","multimodal neuromonitoring","2026-05-04",{"date":224,"type":33},"2026-05-11",{"date":226,"type":20},"2026-07",{"date":228,"type":20},"2029-09",{"name":230,"class":40},"University of Texas Southwestern Medical Center",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":4},"100612637","coast-study---cholesterol-optimization-after-stroke-100612637","NCT07256171","COAST Study - Cholesterol Optimization After Stroke","Cholesterol Optimization After Stroke: a Multicenter Prospective Study on LDL Cholesterol Control in Patients With Acute Stroke.","COAST","Inclusion Criteria:\n\n* • Recent acute cerebrovascular event, defined as a confirmed diagnosis of ischemic stroke, hemorrhagic stroke, or TIA occurring less than 30 days prior to enrollment.\n\n  * Availability of a baseline measured LDL cholesterol value (direct or calculated) at the time of the index event or close to it.\n  * Patients for whom, in routine clinical practice, a lipid-lowering therapy has been indicated and prescribed for secondary prevention (low-fat diet, supplements, statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, fibrates, or other lipid-lowering agents).\n  * Written informed consent obtained and signed by the patient before inclusion. If the patient is unable to provide consent autonomously (e.g., due to aphasia, impaired consciousness, etc.), informed consent will be obtained from a legal representative or proxy, in accordance with applicable regulations.\n\nExclusion Criteria:\n\n* • Comorbidities or conditions preventing 3-month follow-up: e.g., terminal oncological disease with life expectancy \\\u003C3 months, severe cognitive impairment (e.g., advanced dementia), or other conditions that make it impossible to obtain follow-up information; inability to contact the patient after discharge (e.g., non-resident foreign patient or lacking telephone contacts).\n\n  * Any other clinical, psychological, or social condition that, in the investigator's judgment, may compromise the patient's ability to adhere to the study or the reliability of the collected data.",{"count":51,"type":20},"This study (acronym COAST Trial) is a multicenter observational registry aiming to document: patients' adherence and persistence to lipid-lowering therapy prescribed for secondary prevention; the proportion of patients achieving LDL cholesterol therapeutic targets at 3 months; the incidence of cerebrovascular recurrence and mortality at 90 days, as well as the occurrence of any adverse effects from these therapies. This information will provide a snapshot of post-stroke\u002FTIA lipid-lowering management across centers and identify areas for improvement, offering useful data to optimize secondary prevention strategies in everyday clinical practice.",[242,24],"Stroke (CVA) or Transient Ischemic Attack",[244,245,246,247,248,249,250,251,252],"LDL cholesterol","lipid-lowering agents","statins","ezetimibe","bempedoic acid","PCSK9 inhibitors","stroke","cerebral hemorrhage","transient ischemic attack","2025-11-20",{"date":255,"type":33},"2025-12-01",{"date":257,"type":20},"2026-01-01",{"date":259,"type":20},"2026-12-31",{"name":261,"class":40},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":41},"100606206","high-risk-of-death-or-disability-in-brain-hemorrhage-role-of-spot-sign-and-secondary-markers-100606206","NCT07172542","High Risk of Death or Disability in Brain Hemorrhage: Role of Spot Sign and Secondary Markers","Inclusion Criteria:\n\n* Spontaneous intracerebral hemorrhage confirmed by contrast-enhanced CT scan.\n* Follow-up CT scan performed within 24 to 48 hours.\n\nNon-inclusion Criteria :\n\n* Absence of initial contrast-enhanced CT or follow-up CT.\n* Hematoma due to trauma, epidural hematoma (EDH), subdural hematoma (SDH), or subarachnoid hemorrhage (SAH).\n\nExclusion Criteria:\n\n* Patient deceased before the initial contrast-enhanced CT.\n* Major missing clinical data.",{"count":269,"type":20},50,"This study looks at patients with brain hemorrhage to see if a special sign on brain scans, called the \"Spot Sign,\" combined with other scan features, can predict a higher risk of death or disability. By comparing patient outcomes with existing prediction scores, the study aims to understand whether these scan markers provide extra value in identifying patients at higher risk.",[272,24,61,273],"Intracerebral Hemorrhage","Brain Injuries","2025-09-08",{"date":276,"type":33},"2025-09-15",{"date":278,"type":20},"2025-10-15",{"date":280,"type":20},"2026-05-15",{"name":282,"class":40},"Centre Hospitalier de Gonesse",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":293,"conditions":294,"keywords":298,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":41},"100507900","brain-perfusion-evaluation-by-contrast-enhanced-ultrasound-100507900","NCT05893407","Brain PERfusion Evaluation by Contrast-Enhanced UltraSound","Quantification of Cerebral Perfusion at the Patient's Bedside When Performing Contrast-enhanced Ultrasound in Neurointensive Care Patients","PerCEUS","Inclusion Criteria:\n\n* Age ≥18\n* Intensive care unit admission for acute brain injury\n* Proven acute brain injury by CT and\u002For MRI\n* Requiring a contrast ultrasound imaging\n* Informed consent of patient or relative\n\nExclusion Criteria:\n\n* Pregnancy\n* Not sufficient temporal window\n* Contraindications to Sonovue ® : acute coronary syndromes, severe ischemic heart disease (requiring revascularization), pulmonary arterial hypertension \\> 90 mmHg, right-left shunt, ARDS, dobutamine's use, known allergy or adverse reaction to Sonovue®\n* Patient on State Medical Assistance",{"count":292,"type":20},60,"The objective of the study is to assess brain tissue perfusion by contrast-enhanced ultrasound perfusion imaging (PerCEUS) in acute brain injuries. More precisely, it aims :\n\n* to evaluate the heterogeneity of brain perfusion and thus diagnose brain tissue hypoperfusion with contrast-enhanced ultrasound.\n* to correlate contrast-enhanced ultrasound with perfusion measurements by usual multimodal monitoring.",[24,295,201,296,297],"Subarachnoid Hemorrhage","Cerebrovascular Circulation","Perfusion",[299,300,301,302,303,304,305,306,307,308,309,310,311,312],"Brain perfusion","Cerebral blood flow","Diagnostic imaging","Ultrasonography Doppler","Doppler ultrasound","Transcranial Doppler","Contrast enhanced ultrasound","Contrast-enhanced ultrasonography","Contrast ultrasound","Ultrasound perfusion imaging","Ultrasound contrast agent","Intra-cranial pressure","Intracerebral hematoma","Neurocritical care","2025-06-16",{"date":315,"type":33},"2025-06-19",{"date":317,"type":33},"2023-07-21",{"date":319,"type":20},"2025-07",{"name":321,"class":40},"Assistance Publique - Hôpitaux de Paris",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":52,"phases":331,"briefSummary":332,"conditions":333,"keywords":334,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":41},"100448403","active-removal-of-intracerebral-hematoma-via-active-irrigation-100448403","NCT05118997","Active Removal of IntraCerebral Hematoma Via Active Irrigation","Active Removal of IntraCerebral Hematoma Via Active Irrigation of the Ventricular System","ARCH","Inclusion Criteria:\n\n1. Age \\>18 years of age\n2. Need of EVD\n3. Active treatment\n4. Signed informed consent obtained\n\n   a. Based on institutional and country laws\n5. Spontaneous ICH with maximum 30 square cm's\n6. If needed, normal coagulation profile (PT, PTT, platelet count)\n7. Treatment within 72 hours of ictus\n8. Ability to administer 2.0 mg of tPA per day for 3 days\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. No need of EVD\n3. Patient has fixed and dilated pupils\n4. Coagulopathy uncorrectable\n5. Vascular pathology (e.g. Aneurysm involvement, AVM involvement)\n6. Pregnant women",{"count":292,"type":20},[54],"Study evaluating if active irrigation by IRRAflow® with infusion of tPA will reduce the time needed for clearance of intracerebral and intraventricular hemorrhage compared with passive drainage.",[24,147],[116,24,147],"2024-07-30",{"date":337,"type":33},"2024-08-01",{"date":339,"type":33},"2021-10-25",{"date":341,"type":20},"2025-09",{"name":343,"class":98},"IRRAS"]